Device Trial Radar · NCT04034810
Safety and Efficacy of Silk Vista and Silk Vista Baby Flow Diverter for Intracranial Aneurysm Treatment
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
234
Planned (sponsor's estimate)
Start
Nov 4, 2019
Primary completion
Mar 1, 2023
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Balt ExtrusionNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 26, 2019
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The FIRST study is an observational, prospective, multi-center, international, single-arm, study. The aim of the study is to collect safety and efficacy information on the use of the silk vista and silk vista baby flow diverter in order to assess clinical safety and performance of the device for treating intracranial aneurysms. All patients with intracranial aneurysm ruptured or unruptured, whatever the localization of the aneurysm, and treated with silk vista or silk vista baby, will be consecutively enrolled in the study. The patient's inclusion and follow up in the study will occur as part of their usual standard of care.
Conditions
- Intracranial Aneurysm
- Flow Diverter
Interventions
Intracranial aneurysm treated with Silk vista and silk vista babyDevice
Patients with intracranial aneurysm(s) intended to be treated with the silk vista and silk vista baby according to standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Morbi-mortality of silk vista and silk vista baby in the treatment of intracranial aneurysms.Time frame: At 12-months (-3 / + 6 months) post procedure
- Morbi-mortality of silk vista and silk vista baby in the treatment of intracranial aneurysms.Time frame: At 12-months (-3 / + 6 months) post procedure
Locations
29 sites in 9 countries. Site status is shown where the registry gives one.
Universitätsklinik für Neurologie
Salzburg, Austria
CHC Saint Joseph Liège
Liège, Belgium
University Hospital Centre Zagreb
Zagreb, Croatia
26 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.